tirzepatide 3ml vial 60mg/3mL (20mg/mL) Tirzepatide reconstitution chart: complete mixing

The SURMOUNT-1 trial, also published in the New England Journal of Medicine, found that participants lost an average of 16.0% of body weight at the 5mg dose, 21.4% at 10mg, and 22.5% at the highest 15mg dose over 72 weeks, compared to 2.4% in the placebo group with 89% to 96% of participants (depending on dose) reaching at least 5% weight loss

PubMed: 10999493 Ipamorelin Improves Body Composition in Healthy Adults human pilot Svensson J, Johannsson G, Bengtsson BA, et al

Concurrent use with insulin or sulphonylureas significantly increases hypoglycaemia risk, requiring careful dose adjustments before starting Wegovy

causes moderate anemia